Indian Commerce and Industry Minister, Piyush Goyal, has invited retailers of all sizes to join the government-promoted Open Network for Digital Commerce (ONDC). This non-profit company aims to create an open platform for all aspects of e-commerce retail, promoting small retailers’ expansion through e-commerce and reducing the dominance of industry giants. ONDC is formulating a
Emily Marsden is a full-time caregiver to her eight-year-old daughter Daisy who was born with Rett Syndrome, a rare genetic condition that requires round-the-clock specialist nursing care. Doctors warned Daisy only had weeks to live, but two years have passed. However, Emily only receives specialist palliative support for her daughter Monday to Friday, between 9
Tofersen (Qalsody) has been granted accelerated approval by the FDA to treat amyotrophic lateral sclerosis (ALS) patients with SOD1 gene mutations. This marks the first time an ALS drug has been approved under the accelerated approval pathway, and the second ALS drug approved in under 12 months. Tofersen is an antisense oligonucleotide that targets SOD1
Japanese lunar exploration company, ispace, recently attempted to land its first cargo mission on the moon. The company’s Mission 1 lunar lander was expected to softly touch down around 12:40 p.m. ET in the Atlas Crater, located in the northeastern sector of the moon. ispace’s uncrewed mission carried scientific research and other payloads, making it
The Food and Drug Administration (FDA) has granted accelerated approval to Biogen’s new drug, Tofersen, for treating a rare and aggressive form of amyotrophic lateral sclerosis (ALS). The approval was granted as Tofersen has filled an unmet medical need for serious conditions. However, Biogen and its co-developer Ionis must further study Tofersen and verify its
Biogen CEO Christopher Viehbacher commented during the company’s first quarter earnings call that they are not worried about competing with Eli Lilly in the market for Alzheimer’s drugs. Both companies are working toward bringing their respective drugs to the market, with Biogen and Japanese drugmaker Eisai developing leqembi, and Eli Lilly developing donanemab and remternetug.
Following Dominic Raab’s resignation over two upheld complaints of bullying, a former Foreign Office chief is urging Chancellor Rishi Sunak to stand up for the civil service. Sir Simon McDonald, who was Mr Raab’s permanent secretary during his time at the Foreign Office, has called for the prime minister to defend the service from Raab’s